Arthur Franken - Gilde Healthcare


All team members
Arthur Franken
General Partner Healthtech/Therapeutics
The Netherlands

Arthur Franken

General Partner - Healthtech/Therapeutics

Arthur Franken joined Gilde in 2001 and was part of the founding team of Gilde Healthcare. He is focusing on venture and growth capital investments in the biopharm, medtech, diagnostics and digital health sectors. He led the investments in Breath Therapeutics (acquired by Zambon), Conatus Pharmaceuticals (IPO on NASDAQ), FlowCardia (acquired by C. R. Bard), Levicept, Moximed, MTM Laboratories (acquired by Roche), Noema Pharma, ProQR Therapeutics (IPO on NASDAQ), SpliceBio and STAT-Dx (acquired by QIAGEN). He has been involved in numerous investments and divestments including Ablynx (IPO on Euronext, acquired by Sanofi-Aventis), Agendia, Amphista Therapeutics, Axonics (IPO on NASDAQ), Calypso Biotech, Eargo (IPO on NASDAQ), uniQure (IPO on NASDAQ), BG Medicine (IPO on NASDAQ), CVRx (IPO on NASDAQ), FIRE1 and Pieris (IPO on NASDAQ).

He represents Gilde on the boards of Calypso, Levicept, Moximed, Noema Pharma and SpliceBio and served as a board member for Breath Therapeutics, FlowCardia, MTM Laboratories, ProQR Therapeutics and STAT-Dx until the trade sales or IPO.

Prior to joining Gilde he was active in cardiovascular research at the Leiden/Amsterdam Center for Drug Research and TNO. He holds a master’s degree in Biopharmaceutical Sciences from Leiden University, the Netherlands. He is a Dutch national.

Besmire Ahmati

Associate Investor Relations & Fundraising
Besmire Ahmati joined Gilde Healthcare in June 2023 as Associate Investor Relations and Fundraising. She is focused on supporting the firm's fundraising activities, investor relationships and communications. Besmire joins Gilde with previous LP experience from...

Janke Dittmer

General Partner Healthtech
Janke Dittmer joined Gilde in 2011 as a Partner. He led Gilde’s investment in Definiens (acquired by AZ), Sapiens (acquired by Medtronic), Volta Medical, Big Health, FIRE1, Lumeon and Nyxoah (IPO on NASDAQ) and was...

Pommeline Korstanje

Pommeline Korstanje joined Gilde Healthcare in 2024. She is involved in deal sourcing, due diligence, and portfolio management as part of the HealthTech team. She completed her master's degree in Innovation Sciences from Utrecht University,...